Answers are grounded in this paper and cite their sources.
Gastric cancer (GC) remains a major global health burden with limited therapeutic options for advanced disease. Dexmedetomidine (DEX), a clinically approved α2-adrenergic receptor agonist, has shown emerging antitumor potential against GC but suffers from poor tumor accumulation and rapid systemic clearance. In this work, a DEX-loaded hyaluronic acid (HA) nanocarrier (1-HA-2@DEX) was developed to enhance DEX delivery while enabling Cu2+ -responsive fluorescence sensing. The nanocarrier exhibited well-defined structural integrity and optical stability, as confirmed by FT-IR, XRD, and photoluminescence analyses. DEX was efficiently encapsulated with a drug loading content of 7.3 wt% and an encapsulation efficiency of 73%. The fluorescence signal of 1-HA-2@DEX showed sensitive and concentration-dependent quenching toward Cu2+ over 0–200 μM, with a quenching efficiency of ~85.7% at 100 μM and a Stern – Volmer constant of 5.316 × 104 M−1 (R2 = 0.9908), together with good selectivity and recyclability. In vitro studies using SGC-7901 gastric cancer cells demonstrated that the DEX-loaded HA nanocarrier significantly enhanced anticancer efficacy, achieving 58.6% proliferation inhibition at 48 h and effectively suppressing cell invasion, while the blank carrier showed negligible cytotoxicity. Overall, this study presents a DEX-loaded HA nanocarrier that integrates improved therapeutic efficacy with quantitative Cu2 sensing, offering a promising strategy for GC treatment and monitoring.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: